<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-04-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12000 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850263814643122176 |
|---|---|
| author | Emilio Iannitto Simone Ferrero Côme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord Giovanni Roti Fabrice Jardin Barbara Castagnari Francesca Palombi Lucile Baseggio Alexandra Traverse-Glehen Claudio Tripodo Anna Marina Liberati Margherita Parolini Sara Usai Caterina Patti Massimo Federico Maurizio Musso Marco Ladetto Emanuele Zucca Catherine Thieblemont |
| author_facet | Emilio Iannitto Simone Ferrero Côme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord Giovanni Roti Fabrice Jardin Barbara Castagnari Francesca Palombi Lucile Baseggio Alexandra Traverse-Glehen Claudio Tripodo Anna Marina Liberati Margherita Parolini Sara Usai Caterina Patti Massimo Federico Maurizio Musso Marco Ladetto Emanuele Zucca Catherine Thieblemont |
| author_sort | Emilio Iannitto |
| collection | DOAJ |
| format | Article |
| id | doaj-art-c01fa37d2d6946cc89181a7455febe91 |
| institution | OA Journals |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-c01fa37d2d6946cc89181a7455febe912025-08-20T01:54:53ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-04-01110410.3324/haematol.2024.287031<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto0Simone Ferrero1Côme Bommier2Daniela Drandi3Martina Ferrante4Krimo Bouabdallah5Sylvain Carras6Guido Gini7Vincent Camus8Salvatrice Mancuso9Luigi Marcheselli10Angela Ferrari11Michele Merli12Benoit Tessoulin13Caterina Stelitano14Kheira Beldjord15Giovanni Roti16Fabrice Jardin17Barbara Castagnari18Francesca Palombi19Lucile Baseggio20Alexandra Traverse-Glehen21Claudio Tripodo22Anna Marina Liberati23Margherita Parolini24Sara Usai25Caterina Patti26Massimo Federico27Maurizio Musso28Marco Ladetto29Emanuele Zucca30Catherine Thieblemont31La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo, Italy; Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, PalermoDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, TorinoUniversitè Paris Citè, Paris, France; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, ParisDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, TorinoDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, TorinoCHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d’Hématologie Clinique et Thérapie Cellulaire, PessacUniversity Grenoble Alpes, Institute For Advanced Biosciences, INSERM U1209, CNRS UMR 5309, University Hospital, Molecular Biology and Hematology Departments, GrenobleEmatologia AOU delle Marche, AnconaDepartment of Hematology, Centre Henri Becquerel, RouenDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of PalermoFondazione Italiana Linfomi ETS, ModenaAzienda Unitá Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio EmiliaHematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, VareseNantes University Hospital and CRC2 NA, NantesUO Ematologia AO Bianchi-Melacrino-Morelli, Reggio CalabriaUniversitè Paris Citè, ParisDipartimento di Medicina e Chirurgia, Universitá di Parma, AOU di Parma, ParmaEmatologia AOU delle Marche, AnconaDepartment of Hematology, Ravenna Hospital, RavennaHematology Unit, IRCCS Regina Elena National Cancer Institute, RomaLaboratoire d’Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, LyonService d’Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, LyonTumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, PalermoOncohematology Unit, University of Perugia, Azienda Ospedaliera S. Maria, TerniEmatologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”- IRST, MeldolaOspedale Oncologico A. Businco, CagliariU.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, PalermoCHIMOMO Department, University of Modena and Reggio Emilia, ModenaLa Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, PalermoUniversity of Eastern Piedmont, Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, AlessandriaIOSI, Oncology Institute of Southern Switzerland and IOR, Institute of Oncology Research IELSG International Extranodal Lymphoma Study, BellinzonaUniversitè Paris Citè, Paris, France; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Parishttps://haematologica.org/article/view/12000 |
| spellingShingle | Emilio Iannitto Simone Ferrero Côme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord Giovanni Roti Fabrice Jardin Barbara Castagnari Francesca Palombi Lucile Baseggio Alexandra Traverse-Glehen Claudio Tripodo Anna Marina Liberati Margherita Parolini Sara Usai Caterina Patti Massimo Federico Maurizio Musso Marco Ladetto Emanuele Zucca Catherine Thieblemont <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study Haematologica |
| title | <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study |
| title_full | <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study |
| title_fullStr | <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study |
| title_full_unstemmed | <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study |
| title_short | <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study |
| title_sort | i erratum i to bendamustine and rituximab as first line treatment for symptomatic splenic marginal zone lymphoma long term outcome and impact of early unmeasurable minimal residual disease attainment from the brisma ielsg36 phase ii study |
| url | https://haematologica.org/article/view/12000 |
| work_keys_str_mv | AT emilioiannitto ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT simoneferrero ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT comebommier ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT danieladrandi ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT martinaferrante ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT krimobouabdallah ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT sylvaincarras ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT guidogini ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT vincentcamus ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT salvatricemancuso ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT luigimarcheselli ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT angelaferrari ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT michelemerli ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT benoittessoulin ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT caterinastelitano ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT kheirabeldjord ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT giovanniroti ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT fabricejardin ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT barbaracastagnari ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT francescapalombi ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT lucilebaseggio ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT alexandratraverseglehen ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT claudiotripodo ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT annamarinaliberati ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT margheritaparolini ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT sarausai ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT caterinapatti ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT massimofederico ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT mauriziomusso ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT marcoladetto ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT emanuelezucca ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy AT catherinethieblemont ierratumitobendamustineandrituximabasfirstlinetreatmentforsymptomaticsplenicmarginalzonelymphomalongtermoutcomeandimpactofearlyunmeasurableminimalresidualdiseaseattainmentfromthebrismaielsg36phaseiistudy |